EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases

Lu Wang, Yusheng Lin, Zhimeng Yao, Nipun Babu, Wan Lin, Chaoying Chen, Liang Du, Songwang Cai, Yunlong Pan, Xiao Xiong, Qiantao Ye, Hongzheng Ren und 5 weitere

Drug Resistance Updates · 2024

DOI: 10.1016/j.drup.2024.101118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2024. Verfasst von Lu Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China; State Key Laboratory of Bioactive Molecules and D…. Hauptthemen laut MEDLINE: Trastuzumab, Drug Resistance, Neoplasm, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Planning Project of Guangdong Province, Natural Science Foundation of Guangdong Province, Henan University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Resistance to targeted therapy is one of the critical obstacles in cancer management. Resistance to trastuzumab frequently develops in the treatment for HER2+ cancers. The role of protein tyrosine phosphatases (PTPs) in trastuzumab resistance is not well understood. In this study, we aim to identify pivotal PTPs affecting trastuzumab resistance and devise a novel counteracting strategy. METHODS: Four public datasets were used to screen PTP candidates in relation to trastuzumab responsiveness in HER2+ breast cancer. Tyrosine kinase (TK) arrays were used to identify kinases that linked to protein tyrosine phosphate receptor type O (PTPRO)-enhanced trastuzumab sensitivity. The efficacy of small activating RNA (saRNA) in trastuzumab-conjugated silica nanoparticles was tested for PTPRO upregulation and resistance mitigation in cell models, a transgenic mouse model, and human cancer cell line-derived xenograft models. RESULTS: PTPRO was identified as the key PTP which influences trastuzumab responsiveness and patient survival. PTPRO de-phosphorated several TKs, including the previously overlooked substrate ERBB3, thereby inhibiting multiple oncogenic pathways associated with drug resistance. Notably, PTPRO, previously deemed "undruggable," was effectively upregulated by saRNA-loaded nanoparticles. The upregulated PTPRO simultaneously inhibited ERBB3, ERBB2, and downstream SRC signaling pathways, thereby counteracting trastuzumab resistance. CONCLUSIONS: Antibody-conjugated saRNA represents an innovative approach for targeting "undruggable" PTPs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabDrug Resistance, NeoplasmBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesXenograft Model Antitumor AssaysNanoparticlesHumansAnimalsMiceFemaleCell Line, TumorMice, TransgenicAntineoplastic Agents, ImmunologicalReceptor-Like Protein Tyrosine Phosphatases, Class 3Signal Transduction

Stichwörter der Autor:innen

ERBB3 cross-compensationantibody-conjugated RNA drugsmall RNA activationtrastuzumab resistanceundruggable phosphatase PTPRO

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, ImmunologicalReceptor-Like Protein Tyrosine Phosphatases, Class 3ERBB2 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China; State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology,…
  • State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, and Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Gua…
  • Shantou University Medical College, Shantou, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Department of Pathology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China; Department of Pathology, Heping Hospital, Changzhi Medical College, Changzhi, China.

Förderung

  • Science and Technology Planning Project of Guangdong Province
  • Natural Science Foundation of Guangdong Province
  • Henan University of Science and Technology
  • Rijksuniversiteit Groningen
  • National Natural Science Foundation of China

Zitieren

APA

Wang, L., Lin, Y., Yao, Z., Babu, N., Lin, W., Chen, C., Du, L., Cai, S., Pan, Y., Xiong, X., Ye, Q., Ren, H., Zhang, D., Chen, Y., Yeung, S. J., Bremer, E., & Zhang, H. (2024). Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2024.101118

Vancouver

Wang L, Lin Y, Yao Z, Babu N, Lin W, Chen C, et al. Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases. Drug Resistance Updates. 2024. doi:10.1016/j.drup.2024.101118

BibTeX
@article{Wang2024,
  author = {Wang, Lu and Lin, Yusheng and Yao, Zhimeng and Babu, Nipun and Lin, Wan and Chen, Chaoying and Du, Liang and Cai, Songwang and Pan, Yunlong and Xiong, Xiao and Ye, Qiantao and Ren, Hongzheng and Zhang, Dianzheng and Chen, Yexi and Yeung, Sai-Ching Jim and Bremer, Edwin and Zhang, Hao},
  title = {Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases},
  journal = {Drug Resistance Updates},
  year = {2024},
  doi = {10.1016/j.drup.2024.101118}
}
Kostenlos starten →